Cite
HARVARD Citation
Moore, K. et al. (n.d.). 197TiP First-in-human (FIH) phase I/II study of ubamatamab, a MUC16xCD3 bispecific antibody, administered alone or in combination with cemiplimab in patients with recurrent ovarian cancer (OC). Immuno-oncology technology. p. . [Online].